← Leaderboards
Rebekah White
University Of California, San Diego
$4,968,849
Attributed
$6,715,107
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,715,107 · 6
By mechanism
R01$5,314,914 · 3
R21$790,523 · 2
K08$609,670 · 1
Top collaborators
- Stephen Philip Schoenberger3 shared
- Bruce Alan Sullenger2 shared
- Stephanie Irene Fraley1 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Jing Yang$15,168,024
- Michael Bouvet$7,522,814
- Shaochen Chen$8,013,482
- Zhongchao Zhao$509,700
- Jessica Everett$434,781
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant Neoplasm Of PancreasOperative Surgical ProceduresMouse ModelCellsResponseDistantDesignProteinsFutureRecurrencePancreatic Cancer ModelOrganoidsImmunePancreatic Cancer PatientsLaboratoriesInflammationAdjuvantAntibodiesMultidisciplinaryClinical TrialsInflammatoryImplantElectroporation
Grant awards (21)
Utilizing nucleic acid scavengers to elucidate how DNA/RNA-containing DAMPs promote pancreatic cancer metastasis and to mitigate such processes$638,056
R01 · FY2025 · CA
Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer$594,402
R01 · FY2025 · CA · contact PI
3D High Density Collagen I Improves Modeling of Metastatic Pancreatic Cancer$410,115
R21 · FY2025 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$390,030
R01 · FY2025 · CA · contact PI
Utilizing nucleic acid scavengers to elucidate how DNA/RNA-containing DAMPs promote pancreatic cancer metastasis and to mitigate such processes$656,237
R01 · FY2024 · CA
Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer$564,526
R01 · FY2024 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$368,038
R01 · FY2024 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$69,324
R01 · FY2024 · CA · contact PI
Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer$629,181
R01 · FY2023 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$379,660
R01 · FY2023 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$142,734
R01 · FY2023 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$386,010
R01 · FY2022 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$76,984
R01 · FY2022 · CA · contact PI
Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer$419,732
R01 · FY2021 · CA · contact PI
Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification$130,942
R21 · FY2016 · CA · contact PI
Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification$41,971
R21 · FY2016 · CA · contact PI
Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification$207,495
R21 · FY2015 · CA · contact PI
RNA Therapeutics for Pancreatic Cancer$151,821
K08 · FY2014 · CA · contact PI
RNA Therapeutics for Pancreatic Cancer$152,224
K08 · FY2013 · CA · contact PI
RNA Therapeutics for Pancreatic Cancer$152,619
K08 · FY2012 · CA · contact PI
RNA Therapeutics for Pancreatic Cancer$153,006
K08 · FY2011 · CA · contact PI